



BioCryst Pharmaceuticals Inc.
2190 Parkway Lake Drive
Birmingham, AL 35244

Durham, NC Office
4505 Emperor Blvd, Suite 200
Durham, NC 27707

Visit IR website [↗](#)
Sign-up for email alerts [↗](#)

NASDAQ: BCRX ¹

Last Trade:	9.55
Trade Time:	4:06 PM ET Nov 20, 2009
Change:	-0.85 (8.173%)
Day Range	9.54 - 10.00
52-Week Range	0.85 - 13.47
Volume	6,734,100

Share Related Items ²

Market Cap. (Mil) \$	370.763
Shares Out (Mil)	38.823
Float (Mil)	31.681

*Mil = Millions

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

² Share Related information provided by Reuters. Data as of Nov 20, 2009.

Company Profile

BioCryst Pharmaceuticals designs, optimizes, and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. BioCryst has progressed two novel compounds that are in late-stage pivotal trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. The Company's strategic alliances with the U.S. Department of Health and Human Services (HHS)/Biomedical Advanced Research and Development Authority (BARDA), Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited validate its scientific foundation and the utility of its product candidates. ... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Nov 19, 2009 [BioCryst Announces Pricing of Public Offering of Common Stock](#)
- Nov 17, 2009 [BioCryst Announces Proposed Public Offering of Common Stock](#)
- Nov 5, 2009 [BioCryst Receives First Peramivir Order From U.S. Government](#)
- Nov 4, 2009 [BioCryst's Partner Shionogi Files for Peramivir Regulatory Approval in Japan](#)
- Oct 29, 2009 [BioCryst to Present at Oppenheimer Healthcare Conference](#)

Events [\[View all \]](#)

- Nov 4, 2009 [20th Annual Oppenheimer Healthcare Conference](#)
- Oct 29, 2009 11:00 AM ET [BioCryst Third Quarter 2009 Conference Call](#)

Financials [\[View all \]](#)

- Mar 6, 2009 [Annual Report \(10-K\)](#)
- Apr 3, 2009 [Definitive Proxy Statement](#)
- Nov 6, 2009 [Quarterly Report \(10-Q\)](#)
- Jul 31, 2009 [Quarterly Report \(10-Q\)](#)
- May 8, 2009 [Quarterly Report \(10-Q\)](#)

